- Home
- CRDL vs TNYA Comparison
CRDL vs TNYA Comparison
Compare CRDL & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- TNYA
- Stock Information
- Founded
- CRDL 2017
- TNYA 2016
- Country
- CRDL Canada
- TNYA United States
- Employees
- CRDL N/A
- TNYA N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- CRDL Health Care
- TNYA Health Care
- Exchange
- CRDL Nasdaq
- TNYA Nasdaq
- Market Cap
- CRDL 112.4M
- TNYA 111.1M
- IPO Year
- CRDL N/A
- TNYA 2021
- Fundamental
- Price
- CRDL $1.44
- TNYA $0.83
- Analyst Decision
- CRDL Strong Buy
- TNYA Strong Buy
- Analyst Count
- CRDL 2
- TNYA 5
- Target Price
- CRDL $9.00
- TNYA $8.60
- AVG Volume (30 Days)
- CRDL 289.4K
- TNYA 2.5M
- Earning Date
- CRDL 08-11-2025
- TNYA 08-07-2025
- Dividend Yield
- CRDL N/A
- TNYA N/A
- EPS Growth
- CRDL N/A
- TNYA N/A
- EPS
- CRDL N/A
- TNYA N/A
- Revenue
- CRDL N/A
- TNYA N/A
- Revenue This Year
- CRDL N/A
- TNYA N/A
- Revenue Next Year
- CRDL N/A
- TNYA N/A
- P/E Ratio
- CRDL N/A
- TNYA N/A
- Revenue Growth
- CRDL N/A
- TNYA N/A
- 52 Week Low
- CRDL $0.77
- TNYA $0.36
- 52 Week High
- CRDL $2.63
- TNYA $4.06
- Technical
- Relative Strength Index (RSI)
- CRDL 56.90
- TNYA 65.61
- Support Level
- CRDL $1.14
- TNYA $0.79
- Resistance Level
- CRDL $1.42
- TNYA $0.90
- Average True Range (ATR)
- CRDL 0.10
- TNYA 0.07
- MACD
- CRDL 0.01
- TNYA 0.01
- Stochastic Oscillator
- CRDL 83.33
- TNYA 68.09
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.